Cargando…
Lipid-lowering drug targets and Parkinson's disease: A sex-specific Mendelian randomization study
Parkinson's disease (PD) affects millions of individuals worldwide, and it is the second most common late-onset neurodegenerative disorder. There is no cure and current treatments only alleviate symptoms. Modifiable risk factors have been explored as possible options for decreasing risk or deve...
Autores principales: | Zhao, Yangfan, Gagliano Taliun, Sarah A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477004/ https://www.ncbi.nlm.nih.gov/pubmed/36119674 http://dx.doi.org/10.3389/fneur.2022.940118 |
Ejemplares similares
-
Genetically predicted waist-to-hip circumference ratio and coronary artery disease: A sex-specific Mendelian randomization study
por: Ye, Qiang, et al.
Publicado: (2023) -
Associations of lipids and lipid-lowering drugs with risk of stroke: a Mendelian randomization study
por: Qin, Hao, et al.
Publicado: (2023) -
Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization
por: Williams, Dylan M., et al.
Publicado: (2020) -
Ten simple rules for conducting a mendelian randomization study
por: Gagliano Taliun, Sarah A., et al.
Publicado: (2021) -
Sex-Specific Patient Journeys in Early Parkinson's Disease in the Netherlands
por: Vlaanderen, Floris Pieter, et al.
Publicado: (2019)